Form 4: ResMed CFO Brett Sandercock Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's Chief Financial Officer, Brett Sandercock, exercised stock options and sold shares of ResMed common stock on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 8, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., exercised options to acquire 12,000 shares of ResMed common stock at a price of $101.64 per share.
- Simultaneously, Sandercock sold 13,000 shares of ResMed common stock at a price of $211.37 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on February 8, 2024.
- Following these transactions, Sandercock beneficially owns 92,056 shares of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. The use of Rule 10b5-1 plans allows insiders to trade company stock without being accused of acting on non-public information.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across the medical device industry.
- Companies like Medtronic, Stryker, and Boston Scientific also utilize similar mechanisms for executive compensation and stock transactions.
- The specific details of these plans, such as vesting schedules and exercise prices, can vary based on company performance and individual agreements.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/11/2019 | Date options first became exercisable. |
| 02/08/2024 | Date Rule 10b5-1 plan was adopted. |
| 04/30/2024 | Date of ResMed stock purchased through the ResMed Employee Stock Purchase Plan. |
| 05/08/2024 | Date of stock option exercise and sale of shares. |
| 05/10/2024 | Date of signature on the Form 4 filing. |
| 11/14/2025 | Expiration date of the ResMed Common Stock Options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.